Results showed SMC4 could effectively predict the OS and PFI in glioma patients independent of new tumor event(s) (Figure 3H, the top panel) or histologic grade (G2 or G3) (Figure 3H, the bottom panel). This evidence concerns the gene SMC4 and neoplasm.